Nemaura Medical Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nemaura Medical Inc. Nemaura Medical Inc. (NMRD) develops and commercializes non-invasive wearable diagnostic devices and digital healthcare solutions for diabetes management, metabolic health, weight loss, and related conditions; core products include sugarBEAT, a CE-marked Class IIb continuous glucose monitor that uses a disposable adhesive skin patch and rechargeable transmitter to deliver real-time blood glucose readings every five minutes for type 1, type 2 diabetes, and pre-diabetes patients; proBEAT, a wellness-oriented continuous glucose monitoring device for metabolic insights and weight management; Miboko, a virtual clinic combining proBEAT glucose data with personalized coaching for obesity and metabolic health; and the BEAT platform, which integrates digital programs like BEATdiabetes—backed by over a decade of clinical evidence from the Joslin Diabetes Center—for type 2 diabetes prevention, reversal, and management, alongside in-development sensors for continuous lactate monitoring in athletic performance, disease states such as sepsis and COVID-19, and continuous temperature tracking for viral progression and fertility. The company, founded in 2011 by Dr. Faz Chowdhury and headquartered at Loughborough University Science and Enterprise Parks in Loughborough, United Kingdom, with a New York address for U.S. operations, targets diabetes, pre-diabetes, obesity, and wellness markets globally, with products available in Europe, the UAE, and the UK through partnerships including pharmacy chains; it employs contract manufacturers for scalable production and pursues regulatory approvals such as FDA clearance for proBEAT. Recent developments encompass a November 2023 $10 million non-dilutive credit facility to support growth; UK expansion of its metabolic health program with direct-to-consumer offerings combining glucose monitoring and GLP-1 weight management; a 2024 collaboration with Oracle Cerner to integrate continuous glucose technology into healthcare systems; positive 2023 clinical trial results advancing proBEAT toward U.S. market entry; and a September 2025 decision to accept NASDAQ delisting and transition to OTC markets while pursuing strategic partnerships for commercialization and shareholder value.
Reviewing InfuSystem (NYSE:INFU) and Nemaura Medical (OTCMKTS:NMRD)
Important Update on Listing Status and Strategic Direction
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
Nemaura Medical Announces Interim Results from its Collaboration with the UK's National Health Service on its Metabolic Health & Weight Loss Program
Nemaura Medical Announces Participation at HLTH 2023, Las Vegas
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results
Nemaura Medical, Inc. (NMRD) Upgraded to Buy: What Does It Mean for the Stock?
Nemaura Medical Announces SFDA Approval of sugarBEAT®
Nemaura Medical Secures $6.5m in Non-Dilutive Funding
Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023
Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton
Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement